Research graph
References from Clinical phenotypes, endotypes, and biomarker profiles of immediate rituximab hypersensitivity reactions: a prospective pharmacovigilance study. Local targets link to admitted publications; unresolved targets remain external evidence.
Development of therapeutic antibodies for the treatment of diseases
10.1186/s12929-019-0592-z · 2020 · External reference
Descriptive analysis of anaphylactic events reported in the FDA adverse event reporting system (FAERS)
10.1177/22799036261427948 · 2026 · External reference
The immunogenicity of biologic therapies
10.1159/000478077 · 2018 · External reference
Hypersensitivity reactions to biologicals: an EAACI position paper
10.1111/all.14984 · 2022 · External reference
Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes
10.1016/j.jaci.2018.02.018 · 2018 · External reference
Hypersensitivity to biological agents-updated diagnosis, management, and treatment
10.1016/j.jaip.2014.12.006 · 2015 · External reference
Endotypes in immune mediated drug reactions: present and future of relevant biomarkers. An EAACI task force report
10.1111/all.16576 · 2025 · External reference
Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)
10.1016/j.jaip.2020.09.021 · 2021 · External reference
Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris
10.1056/nejmoa2028564 · 2021 · External reference
Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection
10.1182/blood-2011-12-395707 · 2012 · External reference
Clinical features and severity grading of anaphylaxis
10.1016/j.jaci.2004.04.029 · 2004 · External reference
Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective
10.1111/all.13226 · 2017 · External reference
Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies
10.1007/s12016-016-8556-5 · 2018 · External reference
Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: in vitro evaluation of rituximab hypersensitivity by basophil activation test
10.1002/ajh.23329 · 2012 · External reference
The measurement of drug-induced interferon gamma-releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions
10.1111/jdv.14890 · 2018 · External reference
Rituximab hypersensitivity: from clinical presentation to management
10.3389/fphar.2020.572863 · 2020 · External reference
Reactions to rituximab in an outpatient infusion center: a 5-year review
10.1016/j.jaip.2016.06.022 · 2017 · External reference
Assessment of confirmed clinical hypersensitivity to rituximab in patients affected with B-cell neoplasia
10.1155/2020/4231561 · 2020 · External reference
Diagnosis and management of anaphylaxis in precision medicine
10.1016/j.jaci.2017.06.012 · 2017 · External reference
Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations
10.3389/fphar.2016.00171 · 2016 · External reference
Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients
10.1038/s41420-021-00429-9 · 2021 · External reference
Severe hypersensitivity reactions at biosimilar versus originator rituximab treatment initiation, switch and over time: a cohort study on the French national health data system
10.1007/s40259-023-00584-8 · 2023 · External reference
The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence
10.1007/s12325-020-01472-1 · 2020 · External reference
